| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(7 years from now) | |
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
|
US9550780 (Pediatric) | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
| US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11648244 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
|
US11648244 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11564917 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11357772 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11446291 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
| US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
|
US11179386 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
| US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(17 years from now) | |
Austedo Xr is owned by Teva.
Austedo Xr contains Deutetrabenazine.
Austedo Xr has a total of 17 drug patents out of which 0 drug patents have expired.
Austedo Xr was authorised for market use on 17 February, 2023.
Austedo Xr is available in tablet, extended release;oral dosage forms.
Austedo Xr can be used as treatment of tardive dyskinesia, treatment of tardive dyskinesia; a method of treating huntington's chorea, a method of treating huntington's chorea.
The generics of Austedo Xr are possible to be released after 10 June, 2041.
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic